1. P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL. (5th April 2022) Authors: Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Popat, R; Usmani, S; Garfall, A; van de Donk, N; Nahi, H; San-Miguel, J; Oriol, A; Nooka, A; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, M; Bahlis, N; Moreau, P; Besemer, B; Martínez-López, J; Sidana, S; Pei, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗